Glenmark is the leader in India in the Discovery of New molecules both NCEs (New Chemical Entity) and NBEs (New Biological Entity).

Glenmark has a pipeline of 13 molecules – 8 NCEs & 5 NBEs in various stages of preclinical & clinical development.

8 molecules are in clinical stage of development and 4 outlicensing deals have been struck with global pharma majors reaffirming Glenmark’s strength in discovery.

Most molecules in clinical trials are either best-in-class or first-in-class with each molecule having potential peak sales opportunity ranging from USD 1 billion to USD 3 billion.

Over 400 Scientists and extensive R&D facilities spread across the globe combine to form the hub of Glenmark’s R&D activity.

Glenmark has three R&D centres dedicated for drug discovery. NCE research is conducted at the R&D centre in Navi Mumbai–India; NBE research is done at Neuchatel–Switzerland; and the Clinical R&D centre is located in Oxford, United Kingdom.